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Breast cancer detection using automated
whole breast ultrasound and mammography
in radiographically dense breasts
Abstract Purpose: Mammography,
the standard method of breast cancer
screening, misses many cancers,
especially in dense-breasted women.
We compared the performance and
diagnostic yield of mammography
alone versus an automated whole
breast ultrasound (AWBU) plus
mammography in women with dense
breasts and/or at elevated risk of
breast cancer. Methods: AWBU
screening was tested in 4,419 women
having routine mammography (Trial
Registration: ClinicalTrials.gov
Identifier: NCT00649337). Cancers
occurring during the study and
subsequent 1-year follow-up were
evaluated. Sensitivity, specificity and
positive predictive value (PPV) of
biopsy recommendation for mam-
mography alone, AWBU and
mammography with AWBU were
calculated. Results: Breast cancer
detection doubled from 23 to 46 in
6,425 studies using AWBU with
mammography, resulting in an in-
crease in diagnostic yield from 3.6
per 1,000 with mammography alone
to 7.2 per 1,000 by adding AWBU.
PPV for biopsy based on mammog-
raphy findings was 39.0% and for
AWBU 38.4%. The number of
detected invasive cancers 10 mm or
less in size tripled from 7 to 21 when
AWBU findings were added to
mammography. Conclusion:
AWBU resulted in significant cancer
detection improvement compared
with mammography alone. Addi-
tional detection and the smaller size
of invasive cancers may justify this
technology’s expense for women
with dense breasts and/or at high risk
for breast cancer.
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Introduction
Despite progress in identifying risk factors and genetic
markers for breast cancer, approximately 70–80% of cases
occur in women without known major predictors [1–3].
Population-based screening for early detection of breast
cancer is therefore the primary strategy for reducing breast
cancer mortality.
Mammography as the standard imaging method for
breast cancer screening [4] has resulted in reduced breast
cancer mortality. However, the number of cancers escaping
detection with mammography is substantial, particularly in
dense-breasted women, with sensitivity as low as 30–48%
[5]. Computer-aided detection (CAD) improves sensitivity
but does not identify all cancers [6, 7]. The DMIST trial
found an improvement from 55% to 70% in cancer
detection comparing digital with film mammography [8],
suggesting that substantial numbers of cancers are missed
even with digital technology. Mammographically missed
cancer is a particular problem for women with dense
breasts [5, 9]; Boyd et al. showed that the odds for interval
cancers was 17.8-fold higher in extremely dense breasts
compared with fatty breasts [9].
The performance of mammography is reduced for cancer
detection in dense-breasted women as mammograms are
summation images, with all breast tissue overlapping in
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e-mail: sjlee@mednet.ucla.edueach view. Cancers may not be visualized because of
overlying dense breast tissue [10–11]. Mammography can
miss far posterior cancers in the retro-mammary space
because of inadequate positioning of deep tissue [10].
Magnetic resonance imaging (MRI) has recently been
recommended by the American Cancer Society (ACS) to
screen women at very high risk of breast cancer [12].
Though highly sensitive, MRI is costly and may carry risks
from the required contrast media [13]. MRI for breast
cancer screening has also been characterized by lower
specificity, as compared to mammography with a higher
rate of false positives, leading to further follow-up MRI
and/or image-guided biopsy costs [14–17]. For example, a
study by Leach et al. reported MRI specificity of 81%,
compared to 93% specificity in mammography [18].
Griebsch et al. [14] reported MRI as having almost four
times more recalls than mammography for women with
high familial breast cancer risk, and 70% of the recalls did
not involve cancer. Because of lower specificity and higher
cost, compared to mammography, MRI may not be optimal
for breast cancer screening.
Ultrasound is an attractive supplement to mammography
because it is widely available, relatively inexpensive and
well-tolerated by patients [19–21]. Ultrasound images the
tissue to the chest wall in all but the very largest patients,
and is a cross-sectional technique, displaying tissue
without overlap. Early reports using high-resolution ultra-
sound for breast cancer detection have been promising
[22–29], but the time and skill necessary to detect
small, non-palpable tumors with hand-held imaging has
discouraged widespread use [30, 31]. Berg et al. (ACRIN
study) [32] noted that lack of uniformity and shortage of
qualified personnel limit wide implementation of hand-
held imaging.
The automated whole-breast ultrasound (AWBU: Sono-
cine, Inc., 5475 Reno Corporate Dr., Suite 200, Reno, NV
89511) system gathers standardized uniform image sets by
lesser trained personnel, allowing shorter, more efficient
time use by physicians interpreting the studies. Previous
studies have shown that 3D AWBU is feasible [33, 34].
Previous studies have also shown that 3D AWBU has
excellent interobserver variability with 2D benign and
malignant lesions [35]. The aim of this study was to
determine the improvement in diagnostic yield in detecting
non-palpable breast cancer in asymptomatic women with
2D AWBU added to mammography.
Materials and methods
Participants
From January 2003 to July 2007, women were recruited for
AWBU studies at presentation for routine mammography
at eight facilities in Pasadena, Redding, Santa Barbara,
Orange and Solano Beach, CA; Albuquerque, NM;
Atlanta, GA; and Ogden, UT. Study participation was
offered to consecutive asymptomatic women who had BI-
RADS density 3 or 4, heterogeneously or extremely
radiographically dense breasts, family or personal history
of breast cancer, and/or implants, and who were at least
35 years old unless they had a family or personal history of
breast cancer. Women with greater than 7 cm compressed
breast thickness at mammography were specifically not
recruited because of ultrasound’s limited effectiveness in
identifying small masses at these depths, and the resultant
decreased reliability of AWBU for these women. Asymp-
tomatic participants were individually interviewed, given a
detailed verbal explanation of the study protocol and
consent, and interviewed to confirm they were asymptom-
atic. The percentage of women volunteering for AWBU
varied by site. Approximately 5% of those eligible
volunteered at sites that only informed the women of the
study by mail and required them to make AWBU
appointments at the same time as their mammograms. Up
to 25% of women volunteered when informed of the study
by personnel at the breast center and offered immediate
AWBU in conjunction with their mammograms.
The study consent was approved by the Institutional
Review Boards at each hospital, or The Western Institu-
tional Review Board. The consent specifically stated that
AWBU is an investigational procedure meant to supple-
ment, not replace, mammography.
Atotal of 6,425 AWBUexaminations andmammograms
were performed on 4,419 asymptomatic women; 4,991 of
the mammograms were routine screening studies, and
1,434 were annual asymptomatic diagnostic, immediate
review studies (22%), including 776 with previous breast
cancer, 399 with implants and 159 with non-localized
findings such as diffuse nodularity or diffuse breast
tenderness. A third (36%; n=2297) of the mammograms
were digital, and two thirds analog. Participants had the
option of having AWBU concurrent with mammography
(3,951 women) or alternating mammography and AWBU
every 6 months (468 women) according to the preference
of the individual woman. Some women who had had
previous breast cancer or who had a strong family history
of breast cancer preferred to be examined by mammogra-
phy or AWBU at approximately 6-month intervals.
Matching studies were included in the analyses if the
examinations fell within a reasonable window, defined as
34 days for participants opting for concurrent screenings
and 5–8 months for patients alternating techniques.
Participants were included in the analysis if they were
asymptomatic and had at least one pair of matching
examinations within the allowed times. Six paired
examinations were incomplete or probably benign (BI-
RADS 0 or 3), but the patients had not completed follow-
up and were excluded from the analysis. Fifty patients were
excluded for the following reasons: 35 had palpable
findings, including 5 palpable cancers; 15 elected AWBU
after an abnormal mammogram, including 5 cancers, and
735were excluded because the AWBU interpretation was not
blinded to mammography findings. Eleven biopsies were
excluded for the following reasons: six patients had
biopsies over a year after AWBU, including 2 cancers;
four had benign biopsies performed for findings seen
with MRI only; one participant had therapeutic seroma
drainage.
One of ten radiologists, FDA-qualified in mammogra-
phy and with at least 10 years’ experience in breast
ultrasound, interpreted each AWBU study. The mammo-
grams were interpreted by a single radiologist in the usual
manner for that institution. The radiologists were blinded to
the results of the corresponding mammograms or AWBU
studies, and in some cases the same radiologist interpreted
both studies.
The mammograms of all participants with cancers
detected by AWBU were retrospectively reviewed, ensur-
ing that the original reader had not missed a mammo-
graphically detectable cancer. Mammograms and AWBU
studies of all participants with clinically detected interval
cancers occurring within 1 year of a normal mammogram
were similarly reviewed. Mammographic follow-up for at
least 1 year since the index imaging was available for 5,089
examinations (80.0%).
Diagnostic tool
AWBU is a computer-based system for performing and
recording ultrasound of the whole breast (SonoCine, Reno,
NV). The images were collected with multi-frequency
transducers within at least the 7 to 12 mHz range. The
ultrasound systems used are the Phillips iU22, the Siemens
Sequoia, the GE Logiq 9 and the ATL HDI 5000. The
transducer is attached to a computer-guided mechanical
arm, and images acquired in longitudinal rows (acquiring
transverse images), overlapping 7 to 10 mm to ensure
complete coverage. As the transducer faces in more than
95% of the examinations measured 5.2 cm, the width of the
rows without the overlap was about 4.2 to 4.5 cm. In most
women the number of rows varied from 4 to 7 for each
breast. The mechanical arm controls transducer speed and
position, with a trained ultrasound technologist maintain-
ing appropriate contact pressure and orientation vertical to
the skin. Approximately 150–300 images per row are
immediately displayed on the AWBU monitor and then
permanently stored. The interval between recorded images
is 0.8 mm. Typical imaging time is 10–20 min for each
participant, with additional participant preparation times of
5–10 min. Interpretation and reporting time for an
experienced radiologist was 7–10 min per examination
for typical AWBU studies.
AWBU software creates a cine loop of the images for
interpretation, simulating the appearance of real-time
imaging. Each cine loop varies from 2,000 to 5,000 images
depending on breast size, with about 3,000 images for the
average woman. Lesion detection is enhanced by review of
the cine loop at about 10 images per second to simulate
motion through the breast. Single still images are reviewed
only after a possible abnormality has been identified. Any
point on an image can be identified as a distance from the
nipple in a specific radius using spatial registration
recorded as images are acquired. Image review is
optimized by playback on a high-resolution monitor
allowing compressed image size, three-dimensional recon-
struction, andadjustment of contrast, brightness andreview
speed.
Studies were reported according to the American
College of Radiology Breast Imaging Reporting and
Data System (BI-RADS) six-point scale (0= incomplete,
needs additional assessment; 1= normal; 2= benign; 3=
probably benign; 4= suspicious; 5= highly suggestive of
malignancy) [36, 37].
Follow-up
Data were collected for size, stage and grade of cancers
detected by imaging and during a 1-year follow-up period.
When both studies were normal, no further action was
required. If the results of AWBU, mammography or both
required further action, additional evaluation was com-
pleted unless the initial abnormal finding was fully
explained by the other imaging study. For examinations
scored as 0 or 3, additional imaging was performed to
determine the final BI-RADS assessment.
If the BI-RADS score was 4 or 5, a stereotactic
radiographic or ultrasound directed 14 gauge or larger
percutaneous biopsy was performed. If a benign non-high-
risk lesion was diagnosed, no further tissue sampling was
performed. If a focal high-risk lesion, such as atypical
ductal hyperplasia, papillary neoplasm or radial scar, was
discovered, the diagnosis was confirmed by surgical
removal of the lesion. If a malignancy was found, the
lesion was removed surgically by lumpectomy or mastec-
tomy, and a final pathological stage was assigned by the
pathologists in the usual manner for that hospital in
accordance with the American Joint Committee on Cancer
(AJCC) TNM system guidelines. The pathologists were
blinded to the patients’ participation in the study and the
method of cancer detection.
Statistical analysis
Improvements in diagnostic yield were assessed by
calculation of the sensitivity, specificity and positive
predictive value (PPV) for biopsy recommendation based
on mammography plus AWBU, compared with mam-
mography. Analyses were carried out using SAS version
9.1 software [38]. Exact 95% confidence intervals (CI)
were calculated for diagnostic yield [39]. Chi-square test
736statistic was used to compare the number of cancers
detected by AWBU, based on the size of cancer.
McNemar’s test was conducted to compare diagnostic
yield between mammography and AWBU. We compared
the PPV between mammography and AWBU following
methodology proposed by Leisenring [40]. P-values of
less than 0.05 were considered to indicate statistical
significance.
Results
Participants
Ethnic groups in the study (n=4419) were whites (87%; n=
3843), Hispanics (6%; n=248), Asians (3%; n=128) and
blacks (1%; n=61). More than half of the participants
reported never taking hormone replacement therapy (59%;
n=2,618); 11% (n=500) of all participants and 5% (3 out
of 57) of participants found to have breast cancer had
implants. Personal history of breast cancer was reported in
10% of participants (n=432) and first or second degree
relatives with breast cancer in 30% (n=1,314) and 29%
(n=1,280), respectively. Four participants (0.1%) have a
known mutation of BRCA1/2. None of the above-
mentioned breast cancer risk factors were reported by
1,279 (29%). Median age of the study population was
53 years (range=24 to 89).
Breast cancer detection
There were 57 cancers in 56 participants (1.3% of the
sample); one participant had bilateral cancer. Mean age of
participants with breast cancer (n=56) at the time of biopsy
was 57 years; 14 cancers occurred in women younger than
50, and 8 patients were at least 70. Cancer detection was
added for patients in all age groups, but age subsets were
too small for statistical analysis. Three quarters (43 out of
57) of breast cancers were reportedi np a r t i c i p a n t sw i t hn o n -
Table 1 Non-palpable breast cancer detection by imaging method
Cancer types Number
of cancers
Imaged only by AWBU Imaged by both AWBU
and mammography
Imaged by
mammography only
Neither
a
N n (%) 95% CI
b n (%) n (%) n (%)
All cancers 57 23 (40) (27.5,54) 15 (26) 8 (14) 11 (19)
Stage
0 7 1 (14) (0,58) 2 4 0
1 33 17 (51.5) (33.5,69) 10 3 3
2a 10 4 (40) (12,74) 2 0 4
2b 3 0 (0) (0,71) 1 1 1
3a 2 1 (50) (1,99) 0 1 1
3b 2 0 (0) (0,84) 0 0 2
Ductal carcinoma in situ 7 1 (14) (0,58) 2 (28.5) 4 (57) 0 (0)
Invasive cancer 50 22 (44) (30,59) 13 (26) 4 (8) 11 (22)
Invasive ductal 42 18 (43) (28,59) 12 (28.5) 3 (7) 9 (21)
Invasive lobular 8 4 (50) (16,84) 1 (12.5) 1 (12.5) 2 (25)
Grade of invasive cancers
c
I 15 7 (47) (21,73) 5 (33) 1 (7) 2 (13)
II 21 13 (62) (38,82) 5 (24) 0 (0) 3 (14)
III 13 2 (15) (2,45) 2 (15) 3 (23) 6 (46)
Size of invasive cancers
5 mm or less
c 3 1 (33) (1,90.5) 1 (33) 1 (33) 0 (0)
6 to 10 mm 18 13 (72) (46.5,90) 3 (17) 2 (11) 0 (0)
11 to 20 mm 20 6 (30) (12,54) 8 (40) 0 (0) 6 (30)
21 to 50 mm 6 1 (17) (0,64) 1 (17) 1 (17) 3 (50)
over 5 cm 3 1 (33) (1,90.5) 0 (0) 0 (0) 2 (67)
Abbreviations: AWBU, automated whole breast ultrasound; CI, confidence intervals
aInterval cancers detected within a year of negative imaging
b95% confidence intervals for additional cancers detected only by AWBU
cOne tumor was detected as a lymph node metastasis, with no primary tumor identified by mammography, ultrasound or MRI
737familial or familial risk factors; 11 cancers were reported in
participantswithapersonalhistoryandfirst-orsecond-degree
relatives with breast cancer, 8 cancers were reported in
participantswithonlyapersonalhistory,and24werereported
in participants only reporting relatives with breast cancer. No
participants with cancer had a known BRCA mutation. Only
three cancers were observed in participants alternating
AWBU/mammography screenings every 6 months.
Breast cancer detections doubled from 23 to 46 in 6,425
studies using AWBU with mammography, resulting in an
increase in diagnostic yield from 3.6 per 1,000 with
mammography alone to 7.2 per 1,000 by adding AWBU
(an additional 3.6 per 1,000; 95% CI=2.3–5.4). Sensitivity
for mammography alone was 40% (95% CI=27.5–54%; 23
out of 57 cancers), but increased to 81% (95% CI=68–
90%; 46 out of 57 cancers) with the addition of AWBU.
Sensitivity of AWBU alone was 67% (95% CI=53–79%;
38 out of 57).
Table 1 shows significant increases in invasive ductal
cancer detections; 18 out of 42 invasive ductal cancers were
demonstrated by AWBU only (95% CI=28–59%), among
grade I invasive cancers (95% CI=21–73%) and grade II
invasive cancers (95% CI=38–82%). Additional grade III
invasive cancer detections were 15% (95% CI=2–45%).
Significantly smaller invasive tumors were detected by
AWBU;14 out of 21 (p=0.006), or 67% of cancers less than
10mm orless weredetectedonlybyAWBU andnot evident
by mammography. The sensitivity of AWBU for these
tumors was 81% compared with 33% for mammography.
Cancer detections for invasive tumors measuring 11 to
20 mm increased from 8 to 14 with the addition of AWBU.
Selected AWBU and mammography images of a woman
with dense breasts are shown in Fig. 1, demonstrating
bilateralcancersevidentwithAWBUbutnotmammography.
For women with dense or extremely dense breasts
(Table 2), AWBU detected 32 out of 49 cancers or 65%,
compared with 19 out of 49, or 39% for mammography
alone (p=0.02). Addition of AWBU to mammography
more than doubled cancer detections from 19 to 39.
AWBU resulted in more recalls for additional imaging
(Table 3) than mammography (p < 0.001). Recalls were
4.2% for screening mammography and 7.2% for AWBU.
Recalls increased from 4.2 to 9.6% adding AWBU to
mammography, as some AWBU-recalled participants were
the same participants recalled because of mammography
findings. The 208 screening mammography recalls resulted
in 13 cancer diagnoses (yield 6.25%); 465 AWBU recalls
resulted in 38 cancer diagnoses (yield 8.2%).
Specificity based on recalls was 89.9% (95% CI=89.1–
90.6%) for AWBU, 95.15% (95% CI=94.6–95.7%) for
mammography and 98.7% (95% CI=98.35–98.9%) for
combined mammography/AWBU. Table 4 outlines the
likelihood of cancer per biopsy recommendation, i.e., PPV
of cancer. No difference in the probability of cancer was
found according to the type of diagnostic test leading to
biopsy.
Fig. 1 Selected images of a 54-
year-old asymptomatic woman
with dense breasts and no pre-
vious history of breast cancer. a
Craniocaudal digital mammo-
grams taken the same day as the
AWBU study. b Mediolateral
oblique digital mammograms
taken the same day as the
AWBU study. c Transverse
AWBU image of the right breast
at 11:30, 6 cm from the nipple;
white arrow shows a 7 mm,
grade I, stage 1, invasive ductal
carcinoma. d AWBU image of
the left breast at 12:00, 3 cm
from the nipple; two white
arrows show 10 mm, grade I,
stage 1, invasive carcinoma with
lobular carcinoma in situ
738Retrospective review
The only detected invasive cancer over 5 cm was a non-
palpable invasive lobular carcinoma, evident by AWBU but
not visible even in retrospect with mammography. Another
large invasive lobular cancer that occurred early in the study
was not detected prospectively by either mammography or
AWBU, but in retrospect is evident by AWBU.
Review of the interval cancers detected clinically within a
year of negative imaging showed 9 out of 11 were evident in
retrospect by AWBU, and 1 of these was also evident in
retrospect by mammography. Two interval cancers were not
evident on either mammography or AWBU.
Discussion
AWBU with mammography is significantly better than
mammography alone for detecting breast cancer, espe-
cially for dense-breasted women. These women face a
particularly difficult situation, as they may be at higher
risk of developing breast cancer [41] and less likely to
have the cancer detected by standard mammography
screening [9–11].
The improvement in cancer detection of 3.6 per 1,000
demonstrated with AWBU is similar to supplemental yield
findings of earlier studies using hand-held ultrasound
(range = 2.7 to 4.6 per 1,000) [42]. However, AWBU has
several advantages over handheld ultrasound. It (1) is more
reproducible, thorough imaging through the entire breasts;
(2) has higher definition with better contrast and sharpness
and smaller images for review by using a high resolution
2,000 line reading monitor with 3D capability and (3)
allows delayed interpretation at computer monitor-based
read stations with non real-time review, optimizing the
radiologist’s reading environment.
As 82% of interval cancers detected clinically before
the next screening are apparent retrospectively on
Table 2 Non-palpable breast cancer detections by imaging methods and breast density
Breast density
according to
BI-RADS
Number
of patients
Number of
cancers
Imaged only
by AWBU
Imaged by both
AWBU and mammography
Imaged by
mammography only
Neither
a p value
b
N (%) N n (%) 95% CI
c n (%) n (%) n (%)
1 (fatty) 148 (2) 2 1 (50) (1,99) 1 (50) 0 (0) 0 (0)
d
2 (mixed) 1,930 (30) 6 2 (33) (4,78) 2 (33) 1 (17) 1 (17) 1.00
3 (dense) 3,923 (61) 42 15 (36) (21.5,52) 11 (26) 7 (17) 9 (21) 0.13
4 (ex dense) 424 (6.5) 7 5 (71) (29,96) 1 (14) 0 (0) 1 (14) 0.06
3 & 4 4,347 (68) 49 20 (41) (27,56) 12 (24) 7 (14) 10 (20) 0.02
Abbreviations: AWBU, automated whole breast ultrasound; ex dense, extremely dense
aInterval cancers diagnosed within 1 year of negative mammography and AWBU
bp value for comparison of number of cancers detected by AWBU versus mammography
c95% confidence intervals for additional cancers detected only by AWBU
dp value not calculated because of zero cell counts
Table 3 Patient recalls for additional studies by initial imaging method
BI-RADS 0 BI-RADS 3
a BI-RADS 4 or 5
a
Imaging method n/N, % n/N, % n/N, %
All mammograms
b 208/6425, 3.2% 39/6425, 0.6% 59/6425, 0.9%
Screening mammograms 208/4991, 4.2% 39/4991, 0.8%
AWBU 465/6425, 7.2% 77/6425, 1.2% 99/6425, 1.5%
Both mammography and AWBU
c 50/6425, 0.8% 10/6425, 0.15% 24/6425, 0.4%
AWBU only
d 415/6425, 6.45% 67/6425, 1.0% 75/6425, 1.2%
Abbreviations: AWBU, automated whole breast ultrasound
aClass 0 imaging studies changed to class 3, 4, or 5 after evaluation
bIncludes screening and diagnostic mammograms
cStudies where additional imaging was recommended based on both mammography and AWBU findings independently
dStudies with class 1 or 2 mammography, where additional imaging would not otherwise have been recommended
739previous AWBU examinations, we postulate that cancer
detection with AWBU may improve with increased
reader experience and possibly a CAD system. In
addition, available previous comparison studies may
contribute to better sensitivity and fewer recalls.
Assuming that many of the AWBU “missed” cancers
could potentially be avoided, AWBU with mammogra-
phy could have sensitivity approaching 95%. This may
be comparable to the sensitivity of MRI, but at a fraction
of the cost [14, 15, 43, 44].
The 38% PPV of biopsy for AWBU observed in this
study is substantially higher than the 11% PPVof biopsy
prompted by ultrasound in the ACRIN Trial [31], and
higher than the 33% PPV from the Breast Cancer
Surveillance Consortium (BCSC) report [45]. Perhaps
our improvement in PPV occurred because the women
with suspicious findings on either mammography or
ultrasound screening were treated as any other recall
patient in the usual manner for the particular imaging
department. Consequently, the PPV found in this study is
consistent with the PPV found in our institutions in
general. Similarly, the recalled women who were not
biopsied were assigned to a BI-RADS category of 1
(normal), 2 (benign) or 3 (probably benign). The
category-3 women underwent appropriate follow-up,
and the others returned to routine screening.
Additionally, only 71% of invasive cancers detected by
the BCSC were smaller than 20 mm, while in this study
90% were smaller than 20 mm [45]. The smaller size of
invasive cancers detected by adding AWBU to mammog-
raphy suggests that this technology may have the potential
to impact breast cancer survival and treatment options,
though this has not yet been shown.
AWBU was well tolerated by participants and easily
incorporated into breast imaging practice. Many women
who are at increased risk of breast cancer do not meet the
ACS criteria for annual MRI, but could benefit from
more effective screening than mammography alone. The
ease of use and cost at approximately $300 make AWBU
an attractive alternative to MRI for women with dense
breasts, family or personal history of breast cancer, or
other risk factors. AWBU is well accepted by participants
because of less breast compression than mammography,
no exposure to ionizing radiation and no contrast
medium injection.
A limitation of our study is the relatively small number
of participating facilities and radiologists. Another possible
limitation is that AWBU images were collected in trans-
verse (axial) planes. However, 3D reconstruction in
coronal, sagittal or any off-axis planes was possible for
any discovered possible abnormality. The technique itself
is limited, as are other ultrasound techniques, in women
with large breasts. Patient cooperation is also necessary as
motion beyond quiet breathing will degrade the examina-
tion. Plans to expand this research include more centers and
a reader study. Continuing modification of the AWBU
system has already produced fewer recalled participants,
and a CAD system is being developed.
The number of recalls for additional imaging and/or
requiring supplemental hand-held ultrasound is a draw-
back of this technology. This difference is partially
explained by the higher cancer detection rate for AWBU
compared with mammography, and partially by the
availability of comparison AWBU examinations for
only 31% of studies. On the other hand, nearly all
mammograms had previous comparison studies. The
similar PPV for biopsy recommendation based on
AWBU detections compared with mammography find-
ings indicates that AWBU does not lead to an excess of
false-positive biopsies, despite the higher recall rate.
The interval cancer rate of 19.3% demonstrated in this
study is also concerning. In spite of a 100% increase in
cancer detections, the interval cancer rate is similar to the
ACRIN trial [32], which showed only a 55% increase in
detections. Most of the cancers missed at screening were
high grade at the time of discovery. However, 9 of the 11
cancers initially missed with AWBU are visible retro-
spectively and are generally similar in appearance to the
small cancers that were discovered prospectively.
As the study population in both these trials consisted of
difficult-to-image, high-risk subjects, these numbers should
not be compared with the general screening population.
Table 4 Positive predictive value of biopsy recommendation by imaging method/s
Imaging method/s Number of cancers Number of biopsies Percentage positive 95% CI
All positive mammograms 23 59 39.0% 26.6 to 52.6%
All positive AWBU 38 99 38.4% 28.8 to 48.7%
AWBU positive, mammogram negative 23 75 30.7% 20.5 to 42.4%
Mammography and AWBU positive 15 24 62.5% 40.6 to 81.2%
AWBU negative, mammogram positive 8 35 22.9% 10.4 to 40.1%
Abbreviations: AWBU, automated whole breast ultrasound; CI, confidence intervals
740However,wedoanticipatelowsensitivityforcancerdetection
with mammography with this type of study population, as the
imaging characteristics of cancers in the normal-risk, dense-
breastedpopulationaremostlikelythesameasinahigherrisk
similar population.
Conclusion
Limiting AWBU examinations to a high-risk group with
dense breasts, similar to the BRCA1/2 studies with MRI
[40, 41], would dramatically reduce the cost per cancer
diagnosis. In our study 87% of cancer detections added by
AWBU were found in the 68% of studies in women with
dense/very dense breasts. Further study should focus on
better defining the combination of risk factors and imaging
characteristics that warrant supplementation of mammog-
raphy with AWBU.
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